TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20193645
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 to 100 mg
Study: 18923706
Drug: Tribendimidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (200 mg for children, 400 mg for adults)
Study: 18923706
Drug: Albendazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (200 mg for children, 400 mg for adults)
Study: 16168630
Drug: Alprazolam 1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.00 mg
Study: 23932198
Drug: Intra-articular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular tenoxicam injection (20 mg)
Study: 23932198
Drug: Arthrocentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis plus sodium hyaluronate injection
Study: 22341892
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine wound infusion
Study: 22341892
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine with saline wound infusion
Study: 22341892
Drug: Saline wound
Normalized name: GNP Saline Wound Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline wound infusion
Study: 20651413
Drug: Aquatic exercise
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercise and education (AE; aquatic exercise twice a week with once-a-week group education)
Study: 20859682
Drug: Control-concentrate (CC)
Normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control-concentrate (CC) group received 1.0 times their maintenance requirements.
Study: 8109939
Drug: M500 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: M500 tablet formulation (500 mg)
Study: 8109939
Drug: M250 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: M250 tablet formulation (500 mg)
Study: 8109939
Drug: Clinical-trial formulation
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical-trial formulation (500 mg)
Study: 8109939
Drug: Syrup formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup formulation (500 mg) with food
Study: 8109939
Drug: Syrup formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup formulation (500 mg) fasting
Study: 3090987
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (5‐fluorouracil, doxorubicin and cyclophosphamide)
Study: 29269583
Drug: Endobronchial coil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial coil treatment
Study: 30150014
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg once daily administered orally)
Study: 30150014
Drug: Vinorelbine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m2 intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m2 intravenously on day 1 of each 21-day cycle])
Study: 20170878
Drug: Enoxaparin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (0.5 mg/kg IV, 0.3 mg/kg SC)
Study: 20170878
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (40 U/kg IV, 3,000 U maximum)
Study: 15889218
Drug: Oral amoxicillin‐clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin‐clavulanic acid 1.313 g 2 hours before operation (n = 208)
Study: 15889218
Drug: Parenteral amoxicillin‐clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amoxicillin‐clavulanic acid 1.2 g intravenously 30 minutes before surgery (n = 200)
Study: 10506395
Drug: Intensified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified therapy (pravastatin 20‐40 mg with addition of colestyramine and/or nicotinic acid)
Study: 10506395
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (usual care antilipidemic therapy)
Study: 8878253
Drug: Dexamethasone, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 3 mg every eight hours for 48 hr
Study: 30676234
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (blue/red light therapy patch)
Study: 22466910
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with mycophenolate sodium (720 mg/day)
Study: 22466910
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with low-exposure cyclosporine (3-8 ng/mL)
Study: 11205935
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to perform five sequential sit-to-stand transfers in PAOD group (13.0 +/- 0.5 s)
Study: 9204220
Drug: Daily self
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self monitoring of blood pressure
Study: 9204220
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily self monitoring of blood pressure
Study: 3296732
Drug: MTX, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX, 250 mg/m2 followed 1 h later by 5-FU, 600 mg/m2
Study: 3296732
Drug: 5-FU followed
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU followed 1 h later by MTX in the same doses
Study: 29324494
Drug: Glucose-Insulin-Potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-Insulin-Potassium (GIK) - 20 IU of insulin, 10 mEq of potassium chloride in 50 mL of glucose 40%, administered over 60 minutes on anesthetic induction.
Study: 29324494
Drug: Glucose-Insulin-Potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-Insulin-Potassium (GIK)
Study: 26585988
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 2 months (Q2M)
Study: 23732968
Drug: Maintenance cognitive-behavioral
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance cognitive-behavioral therapy (CBT)
Study: 19105803
Drug: Self-acquired stabilizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-acquired stabilizing ortheses (e.g., Aircast, Malleoloc)
Study: 16880771
Drug: Pergolide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.1 mg)
Study: 12717109
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate immediate-release (IR) 100 mg BID
Study: 12717109
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate controlled-release (CR) 200 mg OD
Study: 12717109
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of IR and CR formulations
Study: 23073143
Drug: IR formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR formulation
Study: 23073143
Drug: CR formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR formulation
Study: 8864020
Drug: Catheter flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter flush with buffer solution through the sideport
Study: 8864020
Drug: Washing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washing the pumping unit with an alkaline solution after diverting pump flow at the sideport
Study: 8864020
Drug: Procedures for
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedures for managing decreased insulin flow
Study: 1832382
Drug: Isradipine (IS)
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine (IS) 2.5‐7.5 mg three times daily
Study: 1832382
Drug: Nifedipine (NF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NF) 10‐30 mg three times daily
Study: 6344266
Drug: CMF +
Normalized name: Cyclophosphamide, Methotrexate, and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF + immunotherapy
Study: 22325903
Drug: Atacicept (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (150 mg, subcutaneously, twice weekly for 4 weeks, then weekly) with MMF and tapered CS
Study: 17909753
Drug: Naltrexone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (various doses)
Study: 20561758
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment condition (100mg vs. placebo)
Study: 15777306
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hyperbaric bupivacaine at interspace L3‐4
Study: 15777306
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine through spinal catheter with EMG-guidance (Group CSA)
Study: 15777306
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of bupivacaine (15‐20 mg) at L3‐4 (Group Bolus)
Study: 12572376
Drug: Shutianing Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shutianing Granule (STNG) 9 g, three times a day for 28 days
Study: 12572376
Drug: Composite Yangjiao
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite Yangjiao capsule, 5 capsules each time, three times a day for 28 days
Study: 12572376
Drug: Flunarizine hydrochloride
Normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine hydrochloride capsule, 5 mg, once a day for 28 days
Study: 2944380
Drug: enprostil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: enprostil (35 micrograms twice daily)
Study: 8574332
Drug: misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol (200 micrograms four times daily)
Study: 381599
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (16 mg/day)
Study: 381599
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (96 mg/day)
Study: 381599
Drug: Dexamethasone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (both doses)
Study: 26428286
Drug: Customized configuration
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized configuration for medication alert override reasons
Study: 26428286
Drug: Non-customized configuration
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-customized configuration for medication alert override reasons
Study: 23298374
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg/day for 1 week
Study: 16836164
Drug: 0.3 mg/mL
Normalized name: menthol 0.3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/mL rhPDGF‐BB + beta‐TCP
Study: 16836164
Drug: rhPDGF‐BB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhPDGF‐BB treatment groups
Study: 12776476
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose injection
Study: 12776476
Drug: 25% dextrose
Normalized name: Delflex with 4.25% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dextrose injection
Study: 12776476
Drug: 10% or
Normalized name: Xylocaine 10% Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% or 25% dextrose injection based on patient preference
Study: 10877732
Drug: Hyperbaric bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally
Study: 10877732
Drug: Hyperbaric bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine, 0.5%, 15 mg (3 ml) injected intrathecally with torso elevated 30 degrees
Study: 9165550
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of tacrolimus
Study: 9165550
Drug: Evening dose
Normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dose of tacrolimus
Study: 1375485
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus G‐CSF
Study: 1375485
Drug: Peripheral blood
Normalized name: Peripheral blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells harvested after chemotherapy plus G‐CSF
Study: 3910524
Drug: Vancomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (500 mg six hourly for seven days)
Study: 3910524
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg six hourly for seven days)
Study: 29703793
Drug: MET 1000
Normalized name: Fortamet 1000mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET 1000 mg BID
Study: 29703793
Drug: COMBI (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBI (MET 1000 mg BID + liraglutide 1.2 mg QD s.c.)
Study: 23040114
Drug: Lower hemoglobin
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower hemoglobin levels (≤ 11 g/dL)
Study: 23040114
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels >11-12 g/dL
Study: 23040114
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels >12-13 g/dL
Study: 23040114
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels >13-14 g/dL
Study: 23040114
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels >14-15 g/dL
Study: 23040114
Drug: Hemoglobin levels
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin levels >15 g/dL
Study: 17583621
Drug: Iron-fortified toddler
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified toddler formula (500 mL/day)
Study: 17583621
Drug: Unmodified cow's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmodified cow's milk (500 mL/day)
Study: 12575622
Drug: Palivizumab (SYNAGIS)
Normalized name: palivizumab Injection [Synagis]
DrugBank: Palivizumab (DB00110)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Palivizumab (SYNAGIS) - 5 monthly injections
Study: 9647273
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate powder at a dose of 16 mg/day administered by a metered dose inhaler (Group A)
Study: 9647273
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate aqueous solution at a dose of 80 mg/day administered by a nebulizer (Group N)
Study: 9647273
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate aqueous solution (80 mg/day) combined with salbutamol (3 mg/day) administered by a nebulizer (Group C)
Study: 2480798
Drug: HPA-23 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HPA-23 treatment
Study: 1103207
Drug: Haloperidol (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.035 mg/kg)
Study: 23291729
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose influenza vaccine (30 μg/strain)
Study: 23291729
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose influenza vaccine (15 μg/strain)
Study: 21885537
Drug: Manual lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymph drainage in addition to guidelines and exercise therapy
Study: 21885537
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (guidelines and exercise therapy without manual lymph drainage)
Study: 16675716
Drug: 1 g/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/m² of IV methotrexate over 24 hr (Group 1)
Study: 16675716
Drug: 2 g/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/m² of IV methotrexate over 4 hr (Group 2)
Study: 15723939
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of m‐THPC 6 days before direct endoscopic PDT with 80 to 100 J of light for adults and 60 to 80 J for children
Study: 7701450
Drug: Salbutamol 2
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 2 mg (S2)
Study: 7701450
Drug: Salbutamol 4
Normalized name: Salbutamol 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 4 mg (S4)
Study: 7701450
Drug: Salbutamol 8
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 8 mg (S8)
Study: 7701450
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg (PR)
Study: 333188
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 300 mg every 6 hours for up to 5 days or until 1 day after chest tube removal
Study: 31840263
Drug: Family-focused treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused treatment for childhood depression (FFT-CD)
Study: 24690589
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg per day)
Study: 16808682
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA)
Study: 15046713
Drug: Novel agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agents tested with chemotherapy
Study: 15046713
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of previously studied chemotherapeutic agents
Study: 2526101
Drug: Etodolac (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (600 mg daily)
Study: 17113426
Drug: Diclofenac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (150 mg daily)
Study: 2526101
Drug: Subjective drug
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective drug preference
Study: 334083
Drug: Systemic cloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic cloxacillin therapy
Study: 28244897
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (telmisartan)
Study: 23721363
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (25 mg)
Study: 23721363
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with valsartan (320 mg) and hydrochlorothiazide (25 mg)
Study: 23721363
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with amlodipine (10 mg) and valsartan (320 mg)
Study: 23721363
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with amlodipine (10 mg) and hydrochlorothiazide (25 mg)
Study: 19786244
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of autogenous arteriovenous fistulae
Study: 11583718
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg daily) for 3 months
Study: 8215814
Drug: Imipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (mean maximum daily dose, 143 mg)
Study: 8215814
Drug: Trazodone (255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (255 mg)
Study: 8215814
Drug: Diazepam (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (26 mg)
Study: 8215814
Drug: Antidepressants (Imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (Imipramine and Trazodone)
Study: 3651278
Drug: Alcohol 0.2
Normalized name: benzyl alcohol 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.2 g kg‐1
Study: 3651278
Drug: Alcohol 0.4
Normalized name: isopropyl alcohol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.4 g kg‐1
Study: 3651278
Drug: Alcohol 0.8
Normalized name: isopropyl alcohol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.8 g kg‐1
Study: 29069370
Drug: idd sequential
Normalized name: IDD-3
DrugBank: IDD-3 (DB05427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: idd sequential epirubicin, paclitaxel and cyclophosphamide (iddEPC) q2w
Study: 27364568
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) given alongside measles-rubella and yellow fever vaccines
Study: 27364568
Drug: Fractional intradermal
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional intradermal doses of IPV
Study: 27364568
Drug: Measles-rubella and
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-rubella and yellow fever vaccines co-administered with IPV
Study: 26870801
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine
Study: 3026106
Drug: Poliovirus vaccine
Normalized name: POLIOVIRUS VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poliovirus vaccine